Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial
RCT (n=2,425) found that apabetalone added to standard therapy did not significantly reduce the risk of major adverse cardiovascular events. After a median follow up of 26.5 months the rate was 10.3% for apabetalone vs 12.4% for placebo (HR 0.82, 95% CI 0.65-1.04).
Source:
Journal of the American Medical Association
SPS commentary:
Apabetalone is a BET-protein inhibitor, which facilitates endogenous ApoA-I production and raises HDL levels. A related editorial states that whether apabetalone could fulfill the promise of epigenetic therapeutics remains unclear, but the opportunities presented by the various targets involved in epigenetic control over transcriptional programs for this indication merit further consideration.